亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Peptides, Peptidomimetics And Small Molecule Inhibitors Of The Epstein-Barr Virus Mediated Fusion And Entry Process

技術優勢
Large selection of potential EBV infection inhibitors
詳細技術說明
Discovery of compositions and development of methods for modulating EBV infection in patients. #therapeutics #infectiousdisease
*Abstract

Northwestern researchers have found compositions and developed methods for modulating EBV infection in patients. They have identified proteins, peptides and small molecules, all of which relate to EBV gp42 and function to inhibit viral entry. The design of peptides and peptidomimetics is based on the EBV fusion protein gp42. The peptides bind to gH, gL and/or a gH/gL complex with high affinity at nanomolar concentrations. The researchers also identified other small molecules that inhibit EBV-mediated membrane fusion by targeting the epithelial cells and B-cells. They exhibit effective inhibition, blocking over 50% viral fusions. The compounds may be formulated as pharmaceutical compositions for treating and preventing conditions and diseases associated with EBV infection, such as acute infectious mononucleosis, B-cell lymphomas, other lympho-proliferative diseases, and epithelial cancers associated with EBV.

*Inventors
Theodore Jardetzky Justin Kirschner Richard Longnecker* Jasmina Omerovic
*Publications
Kirschner AN, Omerović J, Popov B, Longnecker R, and Jardetzky TS (2006) Soluble Epstein-Barr Virus Glycoproteins gH, gL, and gp42 Form a 1:1:1 Stable Complex That Acts Like Soluble gp42 in B-Cell Fusion but Not in Epithelial Cell Fusion. Journal of Virology. 80: 9444–9454.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備